NASDAQ:BYSI BeyondSpring (BYSI) Stock Forecast, Price & News $1.25 -0.12 (-8.76%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$1.25▼$1.4050-Day Range$0.89▼$1.3952-Week Range$0.54▼$3.45Volume59,277 shsAverage Volume215,388 shsMarket Capitalization$48.65 millionP/E RatioN/ADividend YieldN/APrice Target$1.25 ProfileProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About BeyondSpring (NASDAQ:BYSI) StockBeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in New York, NY.Read More Receive BYSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BeyondSpring and its competitors with MarketBeat's FREE daily newsletter. Email Address BYSI Stock News HeadlinesMay 31, 2023 | americanbankingnews.comHead-To-Head Survey: BeyondSpring (NASDAQ:BYSI) vs. Kura Oncology (NASDAQ:KURA)May 22, 2023 | finance.yahoo.comIs BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth?June 7, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 18, 2023 | finance.yahoo.comBeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual MeetingMay 14, 2023 | americanbankingnews.comBeyondSpring (NASDAQ:BYSI) & Enlivex Therapeutics (NASDAQ:ENLV) Critical ReviewMay 13, 2023 | americanbankingnews.comMateon Therapeutics (OTCMKTS:MATN) vs. BeyondSpring (NASDAQ:BYSI) Head to Head AnalysisMay 4, 2023 | americanbankingnews.comBeyondSpring (NASDAQ:BYSI) Given New $1.25 Price Target at Robert W. BairdApril 18, 2023 | finance.yahoo.comBeyondSpring Provides Business Update and Reports Year End 2022 Financial ResultsJune 7, 2023 | UNKNOWN (Ad)Lithium Has Boomed And This American Stock Is Ready..Lithium Has Been On A Crazy Rally Over The Last 3 Year's And This Stock Could Be Next!April 18, 2023 | finance.yahoo.comBeyondSpring Files 2022 Annual Report on Form 20-FApril 18, 2023 | sg.finance.yahoo.comBeyondSpring Inc. (BYSI) stock price, news, quote & history – Yahoo FinanceApril 12, 2023 | americanbankingnews.comNeptune Wellness Solutions (NASDAQ:NEPT) versus BeyondSpring (NASDAQ:BYSI) Head-To-Head ReviewMarch 19, 2023 | finance.yahoo.comBeyondSpring Inc. (BYSI) Stock Historical Prices & Data - Yahoo FinanceMarch 2, 2023 | finance.yahoo.comBeyondSpring First Half 2022 Earnings: US$0.47 loss per share (vs US$0.93 loss in 1H 2021)March 1, 2023 | finance.yahoo.comBeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After ImmunotherapyJanuary 9, 2023 | finance.yahoo.comBeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing RulesDecember 20, 2022 | finance.yahoo.comIndividual investors who hold 50% of BeyondSpring Inc. (NASDAQ:BYSI) gained 153%, insiders profited as wellDecember 13, 2022 | finance.yahoo.comWhy Are BeyondSpring Shares Trading Higher?December 13, 2022 | finance.yahoo.comBeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical ConferencesNovember 23, 2022 | finance.yahoo.comBeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsOctober 14, 2022 | theguardian.comEngland could be in drought beyond spring 2023, say ministers - The GuardianSeptember 29, 2022 | uk.finance.yahoo.comBeyondSpring Inc. (BYSI)September 13, 2022 | finance.yahoo.comBeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022 - Yahoo FinanceSeptember 13, 2022 | finance.yahoo.comBeyondSpring's Lead Cancer Drug Protects Bone Marrow Stem Cells Within 24 HoursSeptember 13, 2022 | globenewswire.comBeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022 - GlobeNewswireSeptember 13, 2022 | finance.yahoo.comBeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022September 8, 2022 | seekingalpha.comBeyondSpring Q2 2022 Earnings Preview - Seeking AlphaSee More Headlines BYSI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BYSI Company Calendar Last Earnings12/29/2021Today6/06/2023Next Earnings (Estimated)7/18/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BYSI CUSIPN/A CIK1677940 Webwww.beyondspringpharma.com Phone(646) 305-6387Fax1-646-882-4228Employees91Year FoundedN/APrice Target and Rating Average Stock Price Forecast$1.25 High Stock Price Forecast$1.25 Low Stock Price Forecast$1.25 Forecasted Upside/Downside0.0%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.24 Quick Ratio5.24 Sales & Book Value Annual Sales$1.35 million Price / Sales36.04 Cash FlowN/A Price / Cash FlowN/A Book Value($0.36) per share Price / Book-3.47Miscellaneous Outstanding Shares38,920,000Free Float27,515,000Market Cap$48.65 million OptionableNot Optionable Beta0.10 Key ExecutivesLan HuangChairman & Chief Executive OfficerG. Kenneth LloydChief Scientific OfficerKey CompetitorsRain OncologyNASDAQ:RAINHepion PharmaceuticalsNASDAQ:HEPAEledon PharmaceuticalsNASDAQ:ELDNFSD PharmaNASDAQ:HUGESynlogicNASDAQ:SYBXView All CompetitorsInstitutional OwnershipState Street CorpSold 48,249 shares on 5/16/2023Ownership: 0.097%Susquehanna International Group LLPSold 49,700 shares on 5/16/2023Ownership: 0.000%Two Sigma Investments LPBought 52,452 shares on 5/15/2023Ownership: 0.135%Dimensional Fund Advisors LPBought 24,624 shares on 5/12/2023Ownership: 0.063%Group One Trading L.P.Bought 400 shares on 5/12/2023Ownership: 0.000%View All Institutional Transactions BYSI Stock - Frequently Asked Questions What is BeyondSpring's stock price forecast for 2023? 0 analysts have issued 12-month target prices for BeyondSpring's stock. Their BYSI share price forecasts range from $1.25 to $1.25. On average, they expect the company's share price to reach $1.25 in the next year. View analysts price targets for BYSI or view top-rated stocks among Wall Street analysts. How have BYSI shares performed in 2023? BeyondSpring's stock was trading at $1.88 at the beginning of the year. Since then, BYSI shares have decreased by 33.5% and is now trading at $1.25. View the best growth stocks for 2023 here. When is BeyondSpring's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 18th 2023. View our BYSI earnings forecast. How were BeyondSpring's earnings last quarter? BeyondSpring Inc. (NASDAQ:BYSI) released its quarterly earnings results on Wednesday, December, 29th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.58) by $0.11. The firm had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.34 million. What other stocks do shareholders of BeyondSpring own? Based on aggregate information from My MarketBeat watchlists, some companies that other BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), Pfizer (PFE), Atara Biotherapeutics (ATRA), Dynavax Technologies (DVAX). When did BeyondSpring IPO? (BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO. What is BeyondSpring's stock symbol? BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI." Who are BeyondSpring's major shareholders? BeyondSpring's stock is owned by many different retail and institutional investors. Top institutional shareholders include Decheng Capital Management III Cayman LLC (12.74%), BlackRock Inc. (0.61%), Renaissance Technologies LLC (0.31%), Two Sigma Investments LP (0.13%), State Street Corp (0.10%) and Dimensional Fund Advisors LP (0.06%). How do I buy shares of BeyondSpring? Shares of BYSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BeyondSpring's stock price today? One share of BYSI stock can currently be purchased for approximately $1.25. How much money does BeyondSpring make? BeyondSpring (NASDAQ:BYSI) has a market capitalization of $48.65 million and generates $1.35 million in revenue each year. How can I contact BeyondSpring? BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The official website for the company is www.beyondspringpharma.com. The company can be reached via phone at (646) 305-6387, via email at general@beyondspringpharma.com, or via fax at 1-646-882-4228. This page (NASDAQ:BYSI) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeyondSpring Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.